Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAN008 + temozolomide
- Development stage
- Phase 2
- Lead developer
- CANbridge Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CAN008 + temozolomide is a combination therapy under investigation for the treatment of newly diagnosed glioblastoma. **CAN008 (asunercept)** is a recombinant CD95-Fc fusion protein that inhibits the interaction between the CD95 ligand and the endogenous CD95 receptor. This blocks tumor cell invasive growth, migration, and T-cell apoptosis, resulting in enhanced immune recognition and antitumor immunology. **Temozolomide** is an orally-administered alkylating agent that causes DNA damage in tumor cells. The combination is designed to improve progression-free and overall survival when administered with standard concurrent chemoradiotherapy in newly diagnosed glioblastoma patients[1][2][3][6].
- Other names
- asunercept + temozolomideCD95-Fc fusion protein + temozolomide
02
Targets
FASLG (Fas ligand)DNA
Beyond the preview
Go deeper on CAN008 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAN008 + temozolomide.